Semaglutide also improves blood sugar control by stimulating insulin release when glucose levels rise, offering dual benefits for metabolic health
GLP-1 RAs reduce major cardiovascular events by 14% through multiple mechanisms beyond glucose control, including anti-inflammatory effects and blood pressure reduction SELECT trial proved cardiovascular benefits extend to non-diabetic patients with obesity, showing 20% MACE reduction in those without diabetes Semaglutide, liraglutide, and dulaglutide demonstrate the strongest cardiovascular protection, with proven benefits in large outcome trials These agents provide specific benefits for heart failure with preserved ejection fraction and kidney protection, reducing albuminuria by 24% Current guidelines strongly recommend GLP-1 RAs for patients with established cardiovascular disease, regardless of diabetes status or HbA1c levels The evidence positions GLP-1 receptor agonists as fundamental cardiovascular medications rather than merely diabetes drugs with heart benefits
children with autism had much higher amounts of hair mercury as well as other heavy metals, but in both of these studies the children were much older (mean ages 8.8 years in Saudi Arabia and 4.2 years in Kuwait) than those in the baby hair studies (1224 months of age)
Whilst there is no established causal link between GLP-1 receptor agonists and acquired hypothyroidism, weight loss itself can sometimes unmask underlying thyroid conditions
Theyre not waiting to get sick to seek treatment but are looking for ways to optimize their health now, or at least prevent the onset of chronic or age-related diseases as long as possible
